Radiance Therapeutics, Inc. 2026: Is It Legit? Form D Raise, Investors, Who Is Behind It

Q: What is Radiance Therapeutics, Inc.?

Radiance Therapeutics, Inc. is a Delaware corporation that filed a Form D with the SEC on June 29, 2023 in the Other Health Care industry group. The filing claims Rule 506(b) for an offering of debt.

Q: Is Radiance Therapeutics, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Radiance Therapeutics, Inc. filed a Form D with the SEC on June 29, 2023 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $8,989,186 sold to 51 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Q: Is Radiance Therapeutics, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Radiance Therapeutics, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

Q: How much has Radiance Therapeutics, Inc. raised?

Radiance Therapeutics, Inc. reported $8,989,186 sold from 51 investors of a $10,500,000 total offering as of the Form D filed June 29, 2023.

Q: Who can invest in Radiance Therapeutics, Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1,000.

Q: What is the minimum investment in Radiance Therapeutics, Inc.?

The Form D lists $1,000 as the minimum investment accepted from any outside investor as of June 29, 2023. Issuers can waive their own minimums, and the figure does not include fees.

Q: Who is selling Radiance Therapeutics, Inc. and how are they paid?

The Form D names Wilmington Capital Securities, LLC (CRD 133839), associated with None as the recipient of sales compensation soliciting in CA, FL, IL.

Q: Who is behind Radiance Therapeutics, Inc.?

The Form D lists 5 related persons: Laurence John Marsteller, executive officer, director; Peng John Khaw, director; Marc John Sandroff, director; Ken John Abrahams, director; G. Todd John Silva, executive officer. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Q: Where is Radiance Therapeutics, Inc. located?

The issuer's address on its SEC filings is 7440 N. Oracle Road, Bldg. 1, Tucson, AZ 85704. Its phone number of record is 520-582-0960. It is organized under the laws of Delaware.

Q: How long is the Radiance Therapeutics, Inc. offering open?

The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 4 amendments are on record for this CIK.

AltStreetEDGAR DatabaseRadiance Therapeutics, Inc.
SEC filing record
Primary Source · SEC.gov
Radiance Therapeutics, Inc.2020 vintageRule 506(b)Filing record
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$9M
Investors
51
Min Invest
$1,000
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
Claim freeVerify, $480/yr
What this filing shows·Every sentence is a value as filed on SEC Form D
Radiance Therapeutics, Inc. is a Delaware corporation that first filed a Form D on June 4, 2018 and most recently amended it on June 29, 2023 in the Other Health Care industry group. The offering claims Rule 506(b) and covers debt. Radiance Therapeutics, Inc. reported $8,989,186 sold from 51 investors of a $10,500,000 total offering as of the Form D filed June 29, 2023. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1,000. The Form D names Wilmington Capital Securities, LLC (CRD 133839), associated with None as the recipient of sales compensation soliciting in CA, FL, IL. The issuer's address of record is 7440 N. Oracle Road, Bldg. 1, Tucson, AZ 85704.
Critical Disclosures
What the filings and the regulators have said about this entity that a reader should know first. Each line links to its source. The history, the same event across other issuers, and alerts are in the terminal.
Reporting lapsed · Form D · last filing June 29, 2023
Offering declared to continue beyond a year; annual amendment 13+ months overdue An issuer that stops filing is the case the going-concern flag cannot catch: the report that would have carried it was never filed.
Timeline 
Each line is a fact as filed. The history behind it, the same event across other issuers, and an alert on the next one:Open in the terminal Watch this issuer 
EDGAR Filing Data
Form D — Primary Source
View on SEC.gov 
CIK Number0001742457
Entity NameRadiance Therapeutics, Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address7440 N. Oracle Road, Bldg. 1, Tucson, AZ 85704
Phone(520) 582-0960
Industry / Fund TypeOther Health Care
Securities TypeDebt
First Sale DateDecember 10, 2020
Filing DateJune 29, 2023
Accession Number0001742457-23-000001
Total Offering Amount$10,500,000
Total Amount Sold$8,989,186
Amount Remaining$1,510,814
Total Investors51
Non-Accredited InvestorsNone
Minimum Investment$1,000
Offering DurationIntended to last more than one year
Revenue RangeDecline to Disclose
State (Issuer Address)AZ
Amendment Count8 filings on record
Filings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
D/AJune 29, 20230001742457-23-000001D/AJanuary 21, 20220001742457-22-000001DDecember 29, 20200001742457-20-000002D/AOctober 26, 20200001742457-20-000001DJanuary 23, 20190001742457-19-000003D/AJanuary 23, 20190001742457-19-000002DAugust 3, 20180001742457-18-000002DJune 4, 20180001742457-18-000001
In the Terminal
Filing events
0
none on file
Critical / warning
0 / 0
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
4
closed, dark
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.
Investor
4 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2023-06-29: 1 related person added and 0 removed against the filing of 2022-01-21; 5 now listed. The names are in the Terminal feed.
Laurence John Marsteller
Executive Officer, Director · Tucson, AZ
Peng John Khaw
Director · Tucson, AZ
Marc John Sandroff
Director · Tucson, AZ
Ken John Abrahams
Director · Tucson, AZ
G. Todd John Silva
Executive Officer · Tucson, AZ
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Wilmington Capital Securities, LLCCRD 133839 on BrokerCheck 
Associated broker-dealer: None · Garden City, NY · Soliciting in CA, FL, IL and outside the United States
Questions About Radiance Therapeutics, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Radiance Therapeutics, Inc.?Radiance Therapeutics, Inc. is a Delaware corporation that filed a Form D with the SEC on June 29, 2023 in the Other Health Care industry group. The filing claims Rule 506(b) for an offering of debt.
Is Radiance Therapeutics, Inc. legit?AltStreet does not rate legitimacy; it reports the public record. Radiance Therapeutics, Inc. filed a Form D with the SEC on June 29, 2023 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $8,989,186 sold to 51 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Radiance Therapeutics, Inc. registered with or approved by the SEC?No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Radiance Therapeutics, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Radiance Therapeutics, Inc. raised?Radiance Therapeutics, Inc. reported $8,989,186 sold from 51 investors of a $10,500,000 total offering as of the Form D filed June 29, 2023.
Who can invest in Radiance Therapeutics, Inc.?The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1,000.
What is the minimum investment in Radiance Therapeutics, Inc.?The Form D lists $1,000 as the minimum investment accepted from any outside investor as of June 29, 2023. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling Radiance Therapeutics, Inc. and how are they paid?The Form D names Wilmington Capital Securities, LLC (CRD 133839), associated with None as the recipient of sales compensation soliciting in CA, FL, IL.
Who is behind Radiance Therapeutics, Inc.?The Form D lists 5 related persons: Laurence John Marsteller, executive officer, director; Peng John Khaw, director; Marc John Sandroff, director; Ken John Abrahams, director; G. Todd John Silva, executive officer. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Radiance Therapeutics, Inc. located?The issuer's address on its SEC filings is 7440 N. Oracle Road, Bldg. 1, Tucson, AZ 85704. Its phone number of record is 520-582-0960. It is organized under the laws of Delaware.
How long is the Radiance Therapeutics, Inc. offering open?The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 4 amendments are on record for this CIK.
What is Radiance Therapeutics, Inc.'s revenue?The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Claim this profile, freeVerify this entity, $480/yr
Also filed in June 2023
Carlyle AIP Secondaries Access VIII L.P.
$1.1BHedgePremier/Millennium USA SC LP
$834MHedgePremier/Starboard Value & Opportunity Fund LP
$431MKah Capital Mortgage Credit Fund (US) II, LP
$199MEagle Point SRT Co-Invest I LP
$39MKah Capital Mortgage Credit Fund (Cayman) II, LP
$37MOurCrowd (Investment in RPL) L.P.
$6MFarmTogether Hidden Oaks, LLC
$4MMOONFARE CO-INVESTMENT FUND I US LP
$4MMOONFARE VENTURE PORTFOLIO I (US), LP
$2MAccess Feeder A69 SCSp
$2MAcretrader 230, LLP
$1M
Largest other health care filers, this year and last
Fovea Investment Holdings, LLC146 investors
$800MWaystar Holding Corp.102 investors
$621MTranscarent, Inc.33 investors
$481MROM Technologies, Inc.3,556 investors
$448MSharps Technology Inc.62 investors
$411MPrecision Neuroscience Corp46 investors
$250MCognito Therapeutics Group, Inc.23 investors
$196MRightway Healthcare, Inc.6 investors
$155MVeradermics, Inc40 investors
$135MEmber Management Aggregator, L.P.59 investors
$131MEVMS Holdco, LLC5 investors
$130MEmployee Health Holdings, LP52 investors
$128M
All other health care issuers →Filed in June 2023 →
Also filed in June 2023
LOWE EQUITY PARTNERS LLC5 investors
$1000.0BCorvex Offshore Ltd326 investors
$3.1BEighth Cinven Fund (No.1) Limited Partnership45 investors
$2.3BTiger Global Private Investment Partners XVI, L.P.283 investors
$2.1BGMO Fixed Income Absolute Return Fund (Onshore), a series of GMO Master Portfolios (Onshore), L.P.7 investors
$1.9BISQ Growth Markets Infrastructure Fund, L.P.15 investors
$1.8BOwl Rock Capital Corp III694 investors
$1.8BManaged Fund/Bridgewater Fund Ltd63 investors
$1.7BCortec Group Fund VIII-A, L.P.41 investors
$1.6BCortec Group Fund VIII, L.P.72 investors
$1.6BSandbrook Climate Infrastructure Fund I LP37 investors
$1.4BSandbrook Climate Infrastructure Fund I-B LP28 investors
$1.4B
All other health care issuers →Filed in June 2023 →
EDGAR Links
All FilingsEDGAR Full Text SearchSEC Submissions API
Understand This Filing
How Form D private placements workAccredited investor requirementsAlternative-investment glossary
AltStreet Pro
Compare across asset classes
Pro subscribers access the Intelligence Terminal - normalized comparison of 100+ platforms across every alternative asset class.
Terminal plans from $149/month 
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.